Nivolumab and Ipilimumab Acting as Tormentors of Advanced Tumors by Unleashing Immune Cells and Associated Collateral Damage

• Hauptverfasser: Bushra Khan (Verfasst von), Rowaid M. Qahwaji (Verfasst von), Mashael S. Alfaifi (Verfasst von), Mohammad Mobashir (Verfasst von)
• Format: Buch
• Veröffentlicht: MDPI AG, 2024-05-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Combining immune checkpoint inhibitors, specifically nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4), holds substantial promise in revolutionizing cancer treatment. This review explores the transformative impact of these combinations, emphasizing their potential for enhancing therapeutic outcomes...